[1] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatl. 2017, 67: 370-398.
[2] 区淑华.核昔(酸)类药物治疗慢乙肝停药后复发相关性肝衰竭预后分析.广州.南方医科大学,2016:1-70.
[3] Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther,2012, 35: 1317-1325.
[4] Herlitz LC,Mohan S,Stokes MB,et al. Tenofovir nephrotoxicity:acute tubular necrosis with distinctive clinical,pathological,and mitochondrial abnormalities.Kidney Int, 2010,78:1171-1177.
[5] Gill US, Zissimopoulos A, Al-Shamma S, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk. J Infect Dis,2015, 211: 374-382.
[6] 王宇,饶友义,郭军,余江平. 报告比值比法挖掘富马酸替诺福韦二吡呋酯不良反应信号. 中国药房, 2016,27: 4515-4518. |
